AI PRICE FORECAST
HUM Stock Forecast & AI Price Prediction
Humana · Healthcare · Healthcare Plans
HUM live signal snapshot
HUM last traded at $446.31, up 1.88% on the session, trading within 2.2% of its 52-week high of $456.50. Stock Pulse 247's AI model currently rates HUM a BUY, at 84% model confidence. Short-term momentum is constructive: the 5-, 10- and 20-day moving averages are stacked upward and price is holding above the 50-day average. The model's one-month path points toward roughly $460.78 (3.2% from here).
On the 14-day relative strength index, HUM reads 63.2, showing buyers in control without the stretch of an overbought reading. Its MACD line is above its signal line with a positive histogram (1.77) — upward momentum is accelerating. With the 50-day average at $406.95, 29.3% over the 200-day's $314.83, the longer-term trend structure remains positive.
The average 12-month target from 24 Wall Street analysts is $483.29 (range $280.00–$596.00) — 8.3% upside from where HUM trades now. The current recommendation trend leans bullish: 16 Buy/Strong Buy ratings vs 1 Sell/Strong Sell (and 9 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive HUM dashboard for numbers updated throughout today's session.
About Humana
Humana Inc. (HUM) is a healthcare plans company in the healthcare sector, headquartered in Louisville, KY, United States. Humana Inc. provides medical and specialty insurance products in the United States. It has a market value of about $53.6 billion and roughly 67,060 full-time employees. With a beta of 0.64, the stock has historically moved less than the overall market.
HUM performance vs. the market
HUM is up 74.3% so far in 2026, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). On a one-year view it is up 87.2%, 75.7 points better than the S&P 500. The last month (+6.2%) continues the three-month advance (+15.9%).
| Period | HUM | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +6.2% | +11.4% | −2.3% |
| 3 months | +15.9% | +12.2% | −2.3% |
| Year to date | +74.3% | +22.1% | +11.4% |
| 1 year | +87.2% | +28.3% | +11.5% |
Humana financials at a glance
In the quarter ended Sep 30, 2026, Humana reported revenue of $41.2 billion and net income of $162 million (a 0.4% net margin). Revenue was up 26.1% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 43.5 on trailing earnings of $10.25 per share. Trailing free cash flow was $3.3 billion, and total debt equals 71% of shareholders' equity.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $41.2B | $162M |
| Jun 30, 2026 | $40.9B | $694M |
| Mar 31, 2026 | $39.6B | $1.2B |
| Dec 31, 2025 | $32.5B | −$796M |
HUM vs. its peers
Against 5 of its largest healthcare peers, HUM's +74.3% year-to-date return beats 5 of them. None of them has done better this year.
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| Humana (HUM) | $446.31 | +74.3% | 43.5 | BUY |
| UnitedHealth Group (UNH) | $402.94 | +22.1% | 23.0 | HOLD |
| CVS Health (CVS) | $89.52 | +12.8% | 10.4 | HOLD |
| Elevance Health (ELV) | $429.48 | +22.5% | 18.2 | HOLD |
| The Cigna Group (CI) | $301.45 | +9.5% | 13.3 | HOLD |
| Eli Lilly and (LLY) | $1,437.29 | +33.7% | 46.7 | BUY |
HUM stock: common questions
What is the HUM stock price target?
24 Wall Street analysts put the average 12-month target at $483.29, in a range of $280.00–$596.00, versus a recent price of $446.31. Stock Pulse 247's model projects about $460.78 over the next month.
Is HUM a buy right now?
Our AI model currently rates HUM a BUY at 84% confidence. Among analysts, 16 rate it Buy or Strong Buy, 9 Hold and 1 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has HUM stock performed this year?
HUM is up 74.3% so far in 2026, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). On a one-year view it is up 87.2%, 75.7 points better than the S&P 500. The last month (+6.2%) continues the three-month advance (+15.9%).
What is HUM's 52-week high and low?
HUM has traded between $163.11 and $456.50 over the past 52 weeks; at $446.31 it is within 2.2% of its 52-week high of $456.50.
What sector is HUM in, and who are its peers?
HUM is in the healthcare sector (healthcare plans). Its largest peers on Stock Pulse 247 include UnitedHealth Group (UNH), CVS Health (CVS), Elevance Health (ELV), The Cigna Group (CI).
How accurate is the HUM forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines HUM's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.